Yardstick Research tear-sheet / pharma & life sciences CRM cohort

Methodology · how we score · rubric weights in plain sight · vendors received this sheet seven days before publication and could flag factual errors, never rankings

H1

Identity

• Founded: UNKNOWN. Active in the healthcare data space since at least 2018 based on funding history; exact founding year not surfaced on any public page as of research date. [UNKNOWN]
• HQ: New York, NY [THIRD-PARTY - https://h1.co/resources/press]
• Legal entity: H1 (legal entity name not confirmed on public pages) [UNKNOWN]
• Funding: ~$181M+ total raised. Series C Extension (June 2022): $23M at $773M valuation; Series B/C (November 2021): $100M; Series B (December 2020): $58M. [THIRD-PARTY - https://h1.co/resources/press]
• Headcount: UNKNOWN. Not disclosed on vendor site or LinkedIn as of research date. [UNKNOWN]
• Recent news (last 12 months):
• February 2026 - Named to the 2026 DHNY Hall of Fame after five consecutive years of recognition from Digital Health New York. [THIRD-PARTY - https://h1.co/blog]
• June 2025 - Acquired Veda to address provider data challenges for health plans; strengthens provider data management and roster automation capabilities. [VENDOR-CLAIMED - https://h1.co/resources/press]
• January 2025 - Acquired Ribbon Health and added former FDA Commissioner Dr. Stephen Hahn to the board; unveiled 2025 product roadmap. [VENDOR-CLAIMED - https://h1.co/resources/press]
• January 2025 - Partnership with CTI to streamline clinical trial site selection using H1 real-world data. [VENDOR-CLAIMED - https://h1.co/resources/press]
• April 2024 - Launched H1 Connect, enabling physicians to discover global health and clinical trial opportunities. [VENDOR-CLAIMED - https://h1.co/resources/press]
• Archetype: AI-powered healthcare data and provider intelligence platform. H1 aggregates comprehensive data on healthcare providers, clinical trial sites, prescribers, and payers into a unified intelligence platform. Its core use cases span pharma commercial (prescriber targeting), medical affairs (KOL identification, HCP engagement), clinical operations (site selection, patient recruitment), and health plan administration (provider data management, roster automation). The platform's breadth - from clinical trial site selection to commercial prescriber analytics - makes it a horizontal data intelligence layer rather than a purpose-built CRM or field force tool.

Total score: 68.8 / 100

• Stage fit:
• Foundation (<40 readiness): no - Enterprise procurement only, no self-serve, no transparent pricing. Not suitable for early-stage companies without an active commercial or clinical intelligence function.
• Pilot (40-59): conditional - A single-function pilot (e.g., prescriber identification for a brand launch or site selection for a clinical trial) is feasible, but the platform's value compounds across use cases.
• Scale (60-79): yes - Primary fit zone. 200+ customers across 6 continents, 85% of top 20 pharma companies, 9 of 10 top payers. The January 2025 acquisition of Ribbon Health and the June 2025 Veda acquisition demonstrate active Scale-stage platform expansion.
• Optimization (80+): conditional - The breadth of H1's data assets (provider, clinical, commercial, payer) suits Optimization-stage buyers running integrated cross-functional programs, but the hard pricing-transparency penalty and absence of published compliance documentation limit the confidence level for this designation.
• One-line verdict: Broad healthcare provider intelligence platform serving 85% of top 20 pharma - strong data assets and acquisition-led expansion, held back by no public pricing (hard penalty), no surfaced HIPAA/SOC 2 documentation, and limited named-outcome case studies.

Headline numbers

Dimension scores

Pricing detail

H1 does not publish pricing on any public surface. No tiered plan structure, data subscription rates, API pricing, or implementation fee schedule was found during research.

Hard pricing-transparency penalty applied: no public pricing found. This is a hard penalty (−10 points) rather than a soft penalty (−5 points), reducing the headline score from the pre-penalty total of 78.75 to 68.75 (displayed as 68.8). The hard penalty reflects complete pricing opacity with no market-facing signals even at a band or range level.

H1's pricing model likely involves data subscription licenses with seat-based, use-case-based, or data-volume-based tiers given the breadth of the platform. Buyers should request a detailed pricing proposal directly. No public comparison reference exists.

Integrations

The following integrations are listed in H1's D1 record and are relevant to the pharma-lifesci-crm cohort:

• Veeva Vault CRM - Listed in D1 integrations. H1's API Solutions product is described as enabling integration of "comprehensive provider data and intelligence into your existing systems." Specific Veeva Vault CRM integration architecture, data flows, and sync depth are not publicly documented. [UNKNOWN depth - listed in D1 record]
• Salesforce Health Cloud - Listed in D1 integrations. Specific integration architecture and sync depth are not publicly documented. [UNKNOWN depth - listed in D1 record]

Editorial assessment

H1 has assembled an unusually broad healthcare data platform by acquiring depth rather than building it from scratch: the January 2025 Ribbon Health acquisition added clinical intelligence, and the June 2025 Veda acquisition strengthened provider data management for health plans. The January 2025 addition of former FDA Commissioner Dr. Stephen Hahn to the board is a strategic signal worth noting - it either reflects genuine regulatory depth in the product roadmap or serves as a customer-confidence signal for FDA-regulated pharma buyers. Either way, it is a differentiated credential in a field where regulatory navigation is a material procurement consideration.

The platform's penetration claims - 85% of top 20 pharma companies and 9 of 10 top payers - are among the strongest in the cohort. Named customers at Eli Lilly, Sanofi, AstraZeneca, Amgen, J&J, CVS, Centene, and Memorial Sloan Kettering span the breadth of H1's use cases rather than clustering in one vertical. The API Solutions product and multiple data stream offerings (Clinical Intelligence Streams, Medical Intelligence Streams, Prescriber Universe) reflect a platform designed to serve as a data foundation layer for downstream commercial, medical, and clinical technology systems.

The rubric's hard penalty lands squarely on pricing opacity. H1 provides no market-facing pricing signal whatsoever - no band, no starting-price anchor, no tier description. In a procurement environment where buyers are comparing five to ten platforms simultaneously, the complete absence of pricing information means H1 enters discovery calls at a disadvantage relative to vendors that provide at least a pricing range. Combined with the absence of any publicly surfaced HIPAA compliance documentation, SOC 2 certification, or 21 CFR Part 11 confirmation - despite handling provider data for health plans and pharma companies in regulated contexts - the compliance posture gap forces procurement teams to conduct substantial diligence that a published trust center would resolve. For a company at a $773M+ valuation with 85% top-20-pharma penetration, the absence of a public trust center is an unusual gap.

The acquisition pace (two acquisitions in H1 2025) is worth monitoring. Platform integration risk after rapid M&A is real - buyers committing to multi-year contracts should ask specific questions about how the Ribbon Health and Veda product surfaces are integrated into the core H1 platform and what the roadmap timeline is for unified data access.

Best for

• Stage: Scale (60-79). Conditional for Optimization at buyers running integrated commercial + clinical + payer programs.
• Company profile: Mid-to-large pharmaceutical, biotech, or health plan company with active HCP engagement, clinical trial, and provider data management needs across multiple functions. Buyers that benefit most are those integrating H1 data into an existing Veeva, Salesforce, or analytics platform stack.
• Industry fit: Strong for pharma commercial (prescriber targeting), medical affairs (KOL identification, HCP engagement), clinical operations (site selection, enrollment), and health plan administration (provider data management). Moderate for medical device companies where clinical trial and provider data needs are narrower.
• Sales motion: Enterprise procurement; multi-stakeholder (Commercial + Medical + Clinical Ops + IT). Likely multi-quarter sales cycle. Post-acquisition integration clarity may be needed before commitment.
• Annual tooling budget: $150K-$750K+ estimated (no public data; inference from $773M valuation and 200+ customer base cross-sectional positioning).
• Skip if: You need (a) published HIPAA BAA documentation and SOC 2 audit dates before procurement sign-off, (b) transparent pricing before budget approval, (c) a narrow single-use-case point solution rather than a broad data platform, (d) named outcome case studies with verified methodology before procurement, or (e) post-acquisition integration risk mitigation documentation for Ribbon Health and Veda before committing to the combined platform.

Right-of-reply

H1 received this tear-sheet seven calendar days before publication of the Yardstick Research 2026 Yardstick Report, including all measured numbers, sample outputs, and editorial assessment. H1 was given the opportunity to flag factual errors - incorrect pricing, misquoted feature availability, outdated screenshots, factual misstatement in the editorial assessment. H1 was not given the opportunity to request a score revision, dispute the rubric or its weights, withdraw from inclusion, negotiate ranking placement, or suggest changes to the editorial assessment beyond factual correction. Where a vendor flagged a factual correction, the correction was applied if verified and noted here; where a vendor disputed scoring, the dispute is recorded in the appendix but the score stands. Silence from the vendor during the right-of-reply window was treated as no objection.

Right-of-reply gaps

Specific [UNKNOWN] items surfaced in the dossier and explicitly raised with the vendor in right-of-reply:

1. HIPAA compliance status. Does H1 sign a BAA? Is the platform HIPAA compliant as a business associate handling provider and patient data for health plans and pharma clients?
2. SOC 2 Type II status. Held or not held? Audit date and scope?
3. ISO 27001 status. Held or not held?
4. 21 CFR Part 11 support. Does the platform support 21 CFR Part 11 electronic records for FDA submission contexts?
5. Ribbon Health integration status. How fully integrated is the Ribbon Health product surface into the core H1 platform post-January 2025 acquisition?
6. Veda integration status. Same question for the June 2025 Veda acquisition (provider data management for health plans).
7. Founding year. Year of company incorporation.
8. Current headcount. Post-acquisition combined headcount.
9. Veeva Vault CRM integration architecture. What is the specific data-flow and sync depth?
10. Salesforce Health Cloud integration architecture. Same question.

Sources

H1 first-party: - https://www.h1.co/ - https://h1.co/platform - https://h1.co/company - https://h1.co/legal/privacy-policy - https://h1.co/blog - https://h1.co/resources/press

Third-party: - DHNY Hall of Fame 2026 - https://h1.co/blog - Series C Extension (June 2022, $23M at $773M valuation) - https://h1.co/resources/press - Series B/C (November 2021, $100M) - https://h1.co/resources/press - Series B (December 2020, $58M) - https://h1.co/resources/press - Ribbon Health acquisition (January 2025) - https://h1.co/resources/press - Veda acquisition (June 2025) - https://h1.co/resources/press